EU/3/18/2044

About

On 31 July 2018, orphan designation (EU/3/18/2044) was granted by the European Commission to medac Gesellschaft für klinische Spezialpräparate mbH, Germany, for allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded for the treatment of graft-versus-host disease.

Key facts

Active substance
Allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded
Disease / condition
Treatment of graft-versus-host disease
Date of decision
31/07/2018
Outcome
Positive
Orphan decision number
EU/3/18/2044

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstraße 6
D-22880 Wedel
Germany
Tel. + 49 4103 8006 0
Fax + 49 4103 8006 100
E-mail: contact@medac.de

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating